LSD1-IN-23

Cat. No.: HY-152032

Molecular Formula: $C_{19}H_{13}BrClN_5O_2S$

Molecular Weight: 490.76

Target: Histone Demethylase

Pathway: Epigenetics

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	LSD1-IN-23 is a competitive/non-competitive mixed inhibitor of lysine specific demethylase 1 (LSD1). LSD1-IN-23 has LSD1 inhibitory activity with an IC_{50} value of 0.58 μM. LSD1-IN-23 can be used for the research of neuroblastoma (NB)[1].
IC_{50} & Target	KDM1/LSD1 0.58 μM (IC_{50})
In Vitro	LSD1-IN-23 (Compound 48) (0-100 μM) exhibits effective LSD1 inhibitory activity with an IC_{50} value of 0.58 μM[1]. LSD1-IN-23 (0.005, 0.037, 0.111, 0.333 μM; 72 h) significantly increases global H3K4Me2 in NB cells[1]. LSD1-IN-23 (0.1 μM; 24 h) has synergistic effect combination treatment with Bortezomib in NB cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	CHP134 and IMR32 cells
Concentration:	0.1 μM
Incubation Time:	24 h
Result:	Enhanced cytotoxicity in MYCN-amplified NB cells combination treatment of bortezomib with compound 48.

REFERENCES

[1]. Catherine M Mills, et al. Synthesis and evaluation of small molecule inhibitors of LSD1 for use against MYCN-expressing neuroblastoma. Eur J Med Chem. 2022 Dec 15;244:114818.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA